May 6th, 2021 Cellares raises $82M to drive work on cell therapy ‘factory-in-a-box’
May 06, 2021
Fierce Pharma
Related News
-
March 26, 2024Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
-
March 12, 2024
Cellares Unveils First cGMP Compliant Cell Shuttle in its South San Francisco Center of Excellence
-
November 06, 2023
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
